Literature DB >> 31925465

A novel approach to SBRT patient quality assurance using EPID-based real-time transit dosimetry : A step to QA with in vivo EPID dosimetry.

Christos Moustakis1, Fatemeh Ebrahimi Tazehmahalleh2, Khaled Elsayad3, Francis Fezeu4, Sergiu Scobioala3.   

Abstract

PURPOSE: Intra- and inter-fraction organ motion is a major concern in stereotactic body radiation therapy (SBRT). It may cause substantial differences between the planned and delivered dose distribution. Such delivery errors may lead to medical harm and reduce life expectancy for patients. The project presented here investigates and improves a rapid method to detect such errors by performing online dose verification through the analysis of electronic portal imaging device (EPID) images.
METHODS: To validate the method, a respiratory phantom with inhomogeneous insert was examined under various scenarios: no-error and error-simulated measurements. Simulation of respiratory motions was practiced for target ranges up to 2 cm. Three types of treatment planning technique - 3DCRT (three-dimensional conformal radiation therapy), IMRT (intensity modulated radiation therapy), and VMAT (volumetric modulated arc therapy - were generated for lung SBRT. A total of 54 plans were generated to assess the influence of techniques on the performance of portal dose images. Subsequently, EPID images of 52 SBRT patients were verified. Both for phantom and patient cases, dose distributions were compared using the gamma index method according to analysis protocols in the target volume.
RESULTS: The comparison of error-introduced EPID-measured images to reference images showed no significant differences with 3%/3 mm gamma evaluation, though target coverage was strongly underestimated. Gamma tolerance of 2%/2 mm reported noticeable detection in EPID sensitivity for simulated errors in 3DCRT and IMRT techniques. The passing rates for 3DCRT, IMRT, and VMAT with 1%/1 mm in open field were 84.86%, 92.91%, and 98.75%, and by considering MLC-CIAO + 1 cm (threshold 5%), were 68.25%, 83.19%, and 95.29%, respectively.
CONCLUSION: This study demonstrates the feasibility of EPID for detecting the interplay effects. We recommend using thin computed tomography slices and adding sufficient tumor margin in order to limit the dosimetric organ motion in hypofractionated irradiation with preserved plan quality. In the presence of respiratory and gastrointestinal motion, tighter criteria and consequently using local gamma evaluation should be considered, especially for VMAT. This methodology offers a substantial step forward in in vivo dosimetry and the potential to distinguish errors depending on the gamma tolerances. Thus, the approach/prototype provides a fast and easy quality assurance procedure for treatment delivery verification.

Entities:  

Keywords:  Electronic portal imaging device; In vivo dosimetry; Quality assurance; Real time transit dosimetry; Stereotactic body radiation therapy

Mesh:

Year:  2020        PMID: 31925465     DOI: 10.1007/s00066-019-01549-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  37 in total

1.  A quantification of the effectiveness of EPID dosimetry and software-based plan verification systems in detecting incidents in radiotherapy.

Authors:  Casey Bojechko; Mark Phillps; Alan Kalet; Eric C Ford
Journal:  Med Phys       Date:  2015-09       Impact factor: 4.071

2.  Vorsprung durch Technik: evolution, implementation, QA and safety of new technology in radiotherapy.

Authors:  David I Thwaites; Dirk Verellen
Journal:  Radiother Oncol       Date:  2010-02-18       Impact factor: 6.280

3.  Interfractional trend analysis of dose differences based on 2D transit portal dosimetry.

Authors:  L C G G Persoon; S M J J G Nijsten; F J Wilbrink; M Podesta; J A D Snaith; T Lustberg; W J C van Elmpt; F van Gils; F Verhaegen
Journal:  Phys Med Biol       Date:  2012-09-21       Impact factor: 3.609

4.  The management of respiratory motion in radiation oncology report of AAPM Task Group 76.

Authors:  Paul J Keall; Gig S Mageras; James M Balter; Richard S Emery; Kenneth M Forster; Steve B Jiang; Jeffrey M Kapatoes; Daniel A Low; Martin J Murphy; Brad R Murray; Chester R Ramsey; Marcel B Van Herk; S Sastry Vedam; John W Wong; Ellen Yorke
Journal:  Med Phys       Date:  2006-10       Impact factor: 4.071

5.  Time dependence of intrafraction patient motion assessed by repeat stereoscopic imaging.

Authors:  Mischa S Hoogeman; Joost J Nuyttens; Peter C Levendag; Ben J M Heijmen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

6.  Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy.

Authors:  Yvette Seppenwoolde; Hiroki Shirato; Kei Kitamura; Shinichi Shimizu; Marcel van Herk; Joos V Lebesque; Kazuo Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

7.  Detection of intrafractional tumour position error in radiotherapy utilizing cone beam computed tomography.

Authors:  Feng Xu; Jin Wang; Sen Bai; Yan Li; Yali Shen; Renming Zhong; Xiaoqin Jiang; Qingfeng Xu
Journal:  Radiother Oncol       Date:  2008-09-04       Impact factor: 6.280

8.  Comparison of sources of exit fluence variation for IMRT.

Authors:  Joseph K Gardner; Luke Clews; J James Gordon; Song Wang; Peter B Greer; Jeffrey V Siebers
Journal:  Phys Med Biol       Date:  2009-09-04       Impact factor: 3.609

9.  An EPID-based method for comprehensive verification of gantry, EPID and the MLC carriage positional accuracy in Varian linacs during arc treatments.

Authors:  Pejman Rowshanfarzad; Conor K McGarry; Michael P Barnes; Mahsheed Sabet; Martin A Ebert
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

10.  Anatomy-based, patient-specific VMAT QA using EPID or MLC log files.

Authors:  Dewayne L Defoor; Luis A Vazquez-Quino; Panayiotis Mavroidis; Nikos Papanikolaou; Sotirios Stathakis
Journal:  J Appl Clin Med Phys       Date:  2015-05-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.